HIV Prevention Preparedness Study

The purpose of this study is to provide researchers with information that will help them prepare for a future study to test the efficacy of two anti-HIV vaginal gels. This study will also estimate how likely people living in certain areas are to become infected with HIV and other infections passed during sex.

Study Overview

• Status: Completed
• Conditions: HIV Infections; HIV Seronegativity

Detailed Description

This study is designed to prepare for the implementation of a second study, HPTN 035: A Phase II/III Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women. HPTN 035 requires an average HIV seroincidence rate of 5-6 percent among enrolled participants. The primary objective of the present study is to estimate the rates of HIV seroincidence among women targeted for inclusion in HPTN 035.

Women will be enrolled in this study for 6 to 12 months. Study visits will take place monthly. At each visit, participants will complete a medical/menstrual history and undergo pregnancy testing. Each quarter, participants will undergo a structured interview about sexual practices and will receive HIV and STD tests, education, and counseling. Participants will also undergo a pelvic exam with wet mount testing for bacterial vaginosis, candidiasis, and trichomoniasis. Colposcopic evaluations will be performed at selected sites. Pap smears will be performed at sites with the capacity and expertise to prepare and interpret the smears and provide appropriate follow-up care to participants with abnormal results.

• Study Type: Observational
• Enrollment: 1200

Contacts and Locations

Study Locations

• South Africa
  • Chatsworth, South Africa
    • R.K. Khan Hospital
  • Durban, South Africa
  • Hlabisa, South Africa
    • Medical Research Council
  • Hlabisa, South Africa
• Tanzania
  • Moshi, Tanzania
    • Kilimanjaro Christian Med Ctr
  • Moshi, Tanzania
• Zambia
  • Chililabombwe, Zambia
  • Lusaka, Zambia
  • Lusaka, Zambia
    • Chilenje Clinic, Lusaka, Sambia
  • Lusaka, Zambia
    • Kamwala Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion criteria:

• Sexually active (defined as having had vaginal intercourse at least once in the 3 months prior to screening).
• HIV-uninfected at screening.
• Able and willing to provide adequate locator information for study retention purposes.

Exclusion criteria:

• History of adverse reaction to latex.
• Non-therapeutic injection drug use in the 12 months prior to screening.
• Vaginal intercourse more than an average of 2 times per day in the 2 weeks prior to screening.
• Plans to travel away from the study site for more than 3 consecutive months in the next 12 months.
• Plans to relocate away from the study site in the next 12 months.
• Pregnancy or plans to become pregnant in the next 12 months.
• Pregnancy within 42 days prior to enrollment.
• Enrollment in any other study of a vaginally-applied product.
• Clinically apparent pelvic exam finding involving deep epithelial disruption.
• Diagnosis with a current STD and/or other reproductive tract infection requiring treatment.
• Conditions that would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Study Plan

How is the study designed?

Design Details

• Time Perspectives: Prospective

Collaborators and Investigators

• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborators: National Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
• Investigators: Study Chair: Saidi Kapiga, MD, MPH, SCD, Harvard School of Public Health (HSPH); Study Chair: Gita Ramjee, PhD, South Africa Medical Research Council; Study Chair: Stephen Weiss, PhD, University of Miami

Publications and helpful links

General Publications

• Kapiga S, Kelly C, Weiss S, Daley T, Peterson L, Leburg C, Ramjee G. Risk factors for incidence of sexually transmitted infections among women in South Africa, Tanzania, and Zambia: results from HPTN 055 study. Sex Transm Dis. 2009 Apr;36(4):199-206. doi: 10.1097/OLQ.0b013e318191ba01.
• Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B; HPTN 055 Study Team. The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):93-100. doi: 10.1097/QAI.0b013e31815c71f7.
• Schreiber CA, Sammel M, Hillier SL, Barnhart KT. A little bit pregnant: modeling how the accurate detection of pregnancy can improve HIV prevention trials. Am J Epidemiol. 2009 Feb 15;169(4):515-21. doi: 10.1093/aje/kwn345. Epub 2008 Dec 18.

Study record dates

Study Registration Dates

• First Submitted: October 29, 2002
• First Submitted That Met QC Criteria: October 29, 2002
• First Posted (Estimate): October 30, 2002

Study Record Updates

• Last Update Posted (Estimate): May 14, 2010
• Last Update Submitted That Met QC Criteria: May 13, 2010
• Last Verified: January 1, 2006

More Information

Terms related to this study

• Keywords: HIV Seronegativity; Anti-Infective Agents; Incidence; Gels; Administration, Topical; Vagina; HIV Seroprevalence
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; HIV Infections
• Other Study ID Numbers: HIVNET/HPTN 055